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105Clinical Remission Endoscopic Remission
CELEST: Randomized, double-blinded study with upadacitinib in patients with moderate to severe active 
Crohn’s disease and refractory/intolerant to immunosuppressants or tumor necrosis factor antagonists 
Over 52 weeks, the upadacitinib safety profile was 
consistent with studies in rheumatoid arthritis
220 adults with average daily very soft/liquid stool 
frequency >2.5 or abdominal pain score >2.0, and Simple 
Endoscopic Score for Crohn’s disease >6 (or >4 for 
isolated ileal disease)
Continued clinical remission and endoscopic response were 
observed with upadacitinib at week 52
Upadacitinib demonstrated dose-response for 
endoscopic remission at week 16
Clinical Remission Endoscopic Remission
BID, twice daily; QD, once daily106
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119BACKGROUND & AIMS: We evaluated the efficacy and safety
of upadacitinib, an oral selective Janus kinase 1 inhibitor, in a
randomized trial of patients with Crohn’s disease (CD).
METHODS: We performed a double-blind, phase 2 trial in adults
with moderate to severe CD and inadequate response or intoler-
ance to immunosuppressants or tumor necrosis factor antago-
nists. Patients were randomly assigned (1:1:1:1:1:1) to groups
given placebo; or 3 mg, 6 mg, 12 mg, or 24 mg upadacitinib twice
daily; or 24 mg upadacitinib once daily and were evaluated by
ileocolonoscopy at weeks 12 or 16 of the induction period. Pa-
tients who completed week 16 were re-randomized to a 36-week
period of maintenance therapy with upadacitinib. The primary
endpoints were clinical remission at week 16 and endoscopicFLA 5.6.0 DTD  YGAST63194_prooremission at week 12 or 16 using the multiple comparison pro-
cedure and modeling and the Cochran-Mantel-Haenszel test, with
a 2-sided level of 10%. RESULTS: Among the 220 patients in the
study, clinical remission was achieved by 13% of patients
receiving 3 mg upadacitinib, 27% of patients receiving 6 mg
upadacitinib (P < .1 vs placebo), 11% of patients receiving 12 mg
upadacitinib, and 22% of patients receiving 24 mg upadacitinib
twice daily, and by 14% of patients receiving 24 mg upadacitinib
once daily, vs 11% of patients receiving placebo. Endoscopic
remission was achieved by 10% (P < .1 vs placebo), 8%, 8% (P <
.1 vs placebo), 22% (P < .01 vs placebo), and 14% (P < .05 vs
placebo) of patients receiving upadacitinib, respectively, vs none
of the patients receiving placebo. Endoscopic but not clinicalf  2 May 2020  5:03 pm  ce
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WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
This study evaluated the efficacy and safety of
upadacitinib, an oral selective inhibitor of Janus kinase
1, in a phase 2, randomized trial of patients with
moderate to severe Crohn’s disease.
NEW FINDINGS
Upadacitinib led to endoscopic remission in a significant
proportion of patients during induction therapy,
compared with placebo.
2 Sandborn et al Gastroenterology Vol. -, No. -
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191CLINICAL
ATremission increased with dose during the induction period. Effi-
cacy was maintained for most endpoints through week 52. During
the induction period, patients in the upadacitinib groups had
higher incidences of infections and serious infections vs placebo.
Patients in the twice daily 12 mg and 24 mg upadacitinib groups
had significant increases in total, high-density lipoprotein, and
low-density lipoprotein cholesterol levels, compared with patients
in the placebo group. CONCLUSIONS: In a phase 2 trial of patients
with CD, upadacitinib induced endoscopic remission in a signifi-
cant proportion of patients compared with placebo. Upadacitinib’s
benefit/risk profile supports further development for treatment of
CD. (Clinicaltrials.gov, Number: NCT02365649)LIMITATIONS
This was a phase 2 study that included only 220 patients.
No multiplicity-adjustment for the secondary endpoints
was conducted.
IMPACT
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197Keywords: CELEST Trial; CDAI; JAK Inhibitor; IBD.
rohn’s disease (CD) is a chronic, progressive, in-Upadacitinib’s benefit–risk profile supports further studies
in patients with Crohn’s disease.
Abbreviations used in this paper: AE, adverse event; AP, abdominal pain;
CD, Crohn’s disease; CDAI, Crohn’s Disease Activity Index; CI, confidence
interval; CMH, Cochran-Mantel-Haenszel; CPK, creatinine phosphoki-
nase; CR-70, decrease in Crohn’s Disease Activity Index from baseline by
‡70 points; hs-CRP, high-sensitivity C-reactive protein; IBDQ, Inflamma-
tory Bowel Disease Questionnaire; IL, interleukin; JAK, Janus kinase;
MCP-Mod, multiple comparison procedure and modeling; MI, myocardial
infarction; mITT, modified intent-to-treat; PBO, placebo; PRO, patient-
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232Cflammatory disease of the gastrointestinal tract.
Current goals of therapy are to induce and maintain clinical
and endoscopic remission, prevent relapse, and slow or halt
disease progression.1–3 Currently approved therapies,
including corticosteroids, immunosuppressants, and bio-
logic agents, are not effective in some patients and may be
associated with adverse effects that limit their use.4,5 There
remains an unmet need for additional targeted therapies for
CD that provide short- and long-term benefits as measured
by both patients’ symptoms and endoscopic outcomes.
The 4 members of the Janus kinase (JAK) family (JAK1,
JAK2, JAK3, and tyrosine kinase [TYK] 2) are part of trans-
membrane cytokine receptor complexes that are activated
upon binding of a ligand, leading to recruitment, phosphory-
lation, and activation of signal transducers and activators of
transcription.6,7 Signal transducers and activators of tran-
scription control many functions of innate and adaptive im-
munity, hematopoiesis, and cellular complex processes, such
as cell growth, survival, differentiation, andmigration.7 Several
JAK inhibitors with different selectivity have been studied for
the treatment of CD.8–10 Upadacitinib (ABT-494) is an oral
JAK1 inhibitor with increased selectivity for JAK1 compared
with JAK2, JAK3, and TYK2.11 Upadacitinib down-regulates
multiple proinflammatory cytokines, including interleukin
(IL) 2, IL-4, IL-6, IL-7, IL-9, IL-15, IL-21, and interferon gamma,
that are relevant to the pathogenesis of CD.12,13
The main objectives of the phase 2 CELEST study were
to evaluate the efficacy, safety, and pharmacokinetics of
multiple doses of upadacitinib vs placebo as induction
therapy and upadacitinib as maintenance therapy in adult
patients with moderately to severely active CD, who had
refractory symptoms or were intolerant to immunosup-
pressive treatment or tumor necrosis factor (TNF) antago-
nists, by using a model-based dose-response testing and
estimation statistical method.reported outcome; RA, rheumatoid arthritis; SES-CD, Simplified Endo-
scopic Score for Crohn’s Disease; SF, stool frequency; TNF, tumor ne-
crosis factor. Q20
© 2020 by the AGA Institute. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
0016-5085
https://doi.org/10.1053/j.gastro.2020.01.047
233
234
235
236
237
238
239Methods
Study Design
CELEST was a 52-week, multicenter, randomized, double-
blind, dose-ranging, phase 2 study that consisted of a 16-FLA 5.6.0 DTD  YGAST63194_prooweek placebo-controlled induction period, followed by a 36-
week double-blind maintenance period (Supplementary
Figure 1). CELEST was conducted at 93 sites in 19 countries
in the United States, Europe, Israel, Australia, and New Zealand.
The study protocol was approved by the relevant ethics
committees or institutional review boards. The protocol was
executed in compliance with the Declaration of Helsinki, Good
Clinical Practice guidelines, and applicable local regulations. All
patients provided written informed consent before partici-
pating in any study-related procedures. Protocol deviations
were monitored at study entry and throughout the study
duration.Participants
The study enrolled adult patients (aged 18–75 years) with
confirmed ileal, ileocolonic, or colonic CD for 3 months; active
disease with a CD Activity Index (CDAI) of 220–450; average
daily liquid/very soft stool frequency (SF) 2.5; or daily
abdominal pain (AP) score 2.0, as well as evidence of mucosal
inflammation defined as Simplified Endoscopic Score for CD
(SES-CD) 6 (or 4 for those with isolated ileal disease). The
original protocol was designed to enroll patients with inade-
quate response/intolerance to at least 1 of the TNF antagonists
approved for CD (adalimumab, infliximab, or certolizumab
pegol). The protocol was subsequently amended to includef  2 May 2020  5:03 pm  ce
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310patients with inadequate response/intolerance to azathioprine,
mercaptopurine, or methotrexate. (Full inclusion/exclusion
criteria are in Supplementary Table 1.) Patients could enter the
study while receiving stable doses of aminosalicylates, oral
corticosteroids (equivalent prednisone dose of 30 mg/d or
budesonide of 9 mg/d), methotrexate, and/or CD-related
antibiotics but had to discontinue azathioprine or mercapto-
purine 10 days before baseline. Starting at week 2, patients
receiving oral corticosteroids initiated a mandatory cortico-
steroid tapering following a protocol-specified schedule until
discontinuation (Supplementary Table 2).311
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ATRandomization and Masking
At baseline, patients were randomized (1:1:1:1:1:1) to
receive double-blind, 16-week induction treatment with pla-
cebo or the immediate-release formulation of upadacitinib 3-
mg, 6-mg, 12-mg, or 24-mg twice daily or 24-mg once daily
oral doses. The randomization was stratified by endoscopic
disease severity (SES-CD <15 and 15), prior TNF antagonist
use (yes or no), and participation in the substudy of gene
expression in intestinal biopsy specimens (yes or no). Patients
were equally randomized for the follow-up ileocolonoscopy at
either week 12 or 16 for evaluation of the optimal timing of
endoscopic assessment for future studies. Patients were cen-
trally randomized using interactive response technology. The
patients, investigators, site coordinators, and sponsor were
blinded to treatment assignment.
All patients who completed the 16-week induction period
were re-randomized 1:1:1 to receive double-blind maintenance
therapy with the immediate-release formulation of upadacitinib
at 3 mg twice daily, 12 mg twice daily, or 24 mg once daily for
36 weeks.
With the availability of results from phase 1 studies
assessing the 24-mg once daily dose compared with the 12-mg
twice daily dose and from rheumatoid arthritis (RA) phase 2
studies showing the efficacy of the 6-mg twice daily dose, the
24 mg once daily arm in the maintenance period was stopped,
and a 6 mg twice daily arm was initiated in a protocol
amendment. Patients who were already assigned to 24 mg once
daily continued to receive this dosage to the end of the study.
After the protocol amendment, all subsequent patients entering
the maintenance period were re-randomized 1:1:1 to receive
upadacitinib 3 mg, 6 mg, or 12 mg twice daily. The re-
randomization was stratified by dose received during the first
16 weeks and clinical response (clinical responder vs nonre-
sponder) at week 16. Clinical response was defined as a 30%
reduction from baseline in SF and/or AP score, with neither
parameter worse than patients’ baseline score.347
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359Procedures
Eligible patients were assessed at baseline and weeks 2, 4,
8, 12, 16, 20, 28, 36, 44, and 52 for vital signs, physical ex-
amination, patient-reported outcome (PRO) measures, CDAI,
adverse events (AEs), and blood laboratory test results. Stool
samples were collected for fecal calprotectin measurements at
baseline and weeks 4, 16, 28, and 52. SF, AP score, and general
well-being were collected daily using electronic patient diaries
for the CDAI calculation, and SF and AP score were also
calculated as an average from 7 days before the study visit for
the PRO-related clinical endpoints. The Inflammatory BowelFLA 5.6.0 DTD  YGAST63194_prooDisease Questionnaire (IBDQ) was completed at baseline and
weeks 8, 16, and 52. One plasma sample for the determination
of upadacitinib concentration was collected at each postbase-
line study visit. Ileocolonoscopies performed during screening,
week 12 or 16, and week 52 for the SES-CD were centrally read
for eligibility and for the efficacy assessments by readers who
were blinded to patient data and timepoints. The SES-CD data
at weeks 12 and 16 were pooled for the induction period
assessments.Outcomes
The coprimary endpoints of this study were clinical
remission at week 16 (hereafter called clinical remission 1.5/1.0
and defined as average daily SF of 1.5 and AP score of 1.0,
with neither worse than the baseline value) and endoscopic
remission at week 12/16 (defined as SES-CD od 4 and a 2-
point reduction from baseline, with no subscore >1).14
Key prespecified secondary endpoints assessed during the
induction and maintenance periods at various timepoints
included clinical remission 1.5/1.0; endoscopic remission;
endoscopic response 25% (defined as 25% reduction in SES-
CD from baseline); clinical response; CDAI <150 and decrease
in CDAI from baseline 70 points (CR-70); combined clinical
remission 1.5/1.0 and endoscopic remission (referred to as
Remission) and combined clinical response and endoscopic
response 25% (referred as Response); corticosteroid-free and
CDAI <150, corticosteroid-free clinical remission 1.5/1.0,
endoscopic remission and Remission; and change from baseline
in fecal calprotectin, serum high-sensitivity C-reactive protein
(hs-CRP), and IBDQ response (increase in IBDQ 16 points
from baseline) and IBDQ remission (IBDQ 170). Clinical
remission 1.5/1.0 was also assessed in patients with SF 2.5
and AP score 2.0 at baseline and in those with isolated ileal
disease.
Two exploratory secondary endpoints of clinical remission
2.8/1.0 (defined as SF 2.8 and AP score 1.0, neither worse
than baseline, among patients with baseline SF 4.0 or AP
score 2.0) and endoscopic response 50% (defined as >50%
reduction in SES-CD or endoscopic remission) were incorpo-
rated into the statistical analysis plan before the database lock.
Clinical remission 2.8/1.0 emerged while the trial was ongoing
as a more suitable clinical outcome measure for patients with
moderate to severe CD, and endoscopic response 50% was
chosen as a reliable predictor of the 1-year outcomes with the
potential to adequately demonstrate the endoscopic improve-
ment in a clinical trial setting.15,16
Treatment-emergent AEs were monitored in all patients
who received at least 1 dose of study medication from the time
of first administration to 30 days after discontinuation of the
study drug. Serious AEs were collected from the date of signed
informed consent. AEs were tabulated by system organ class
and preferred term using the Medical Dictionary for Regulatory
Activities, version 20.0. Changes from baseline in laboratory
parameters were categorized according to Common Toxicity
Criteria, version 4.03 or version 3.0 (for hemoglobin only).Statistical Analysis
The sample size was calculated based on the multiple
comparison procedure and modeling (MCP-Mod) approach,
which is a data analysis methodology that combines multiplef  2 May 2020  5:03 pm  ce
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Table 1.Baseline Patient Demographics and Disease Characteristics
CharacteristicsQ32
Placebo
n ¼ 37
Upadacitinib
3 mg BID
n ¼ 39
6 mg BID
n ¼ 37
12 mg BID
n ¼ 36
24 mg BID
n ¼ 36
24 mg QD
n ¼ 35
Female, n (%) 24 (64.9) 19 (48.7) 21 (56.8) 17 (47.2) 25 (69.4) 19 (54.3)
Age, y, median (range) 40 (20–68) 37 (19–66) 39 (22–76) 41 (19–70) 44 (20–65) 41 (21–64)
CD duration, y, median
(range)
8.7 (1.2–41.6) 10.7 (0.1–44.7) 8.8 (2.2–46.4) 9.1 (1.2–38.3) 14.1 (1.1–35.5) 10.8 (0.7–36.3)
Disease location, n (%)
Ileal only 9 (24.3) 10 (25.6) 6 (16.2) 5 (13.9) 6 (16.7) 10 (28.6)
Colonic only 6 (16.2) 9 (23.1) 13 (35.1) 11 (30.6) 11 (30.6) 10 (28.6)
Ileocolonic 22 (59.5) 20 (51.3) 18 (48.6) 20 (55.6) 19 (52.8) 15 (42.9)
CDAI, median (range) 276.0 (188–447) 288.0 (180–445) 296.0 (230–599) 280.0 (224–446) 277.5 (162–556) 305.0 (231–421)
Daily very soft/liquid SF,
median (range)
5.7 (1.9–12.4) 5.1 (0.3–15.7) 6.8 (2.6–22.1) 5.7 (2.0–14.7) 4.9 (0.1–19.7) 6.4 (2.6–12.6)
Daily AP score, median
(range)
1.7 (0.9–3.0) 1.9 (0.8–3.0) 1.9 (1.0–3.0) 2.0 (0.4–3.0) 1.7 (0.3–2.9) 2.0 (0.9–3.0)
SES-CD, median (range) 15.0 (4–37) 12.0 (4–32) 14.0 (4–35) 12.5 (4–38) 12.0 (5–29) 12.0 (4–31)
hs-CRP, mg/L, median
(range)
7.0 (0–179) 6.0 (1–308) 11.7 (0–72) 16.6 (1–117) 5.9 (1–135) 7.4 (0–98)
Fecal calprotectin, mg/g,
median (range)
896.0 (126–9600) 916.0 (11–9600) 1602.5 (81–9600) 1622.0 (71–9600) 1377.0 (39–8087) 814.0 (76–9600)
Baseline corticosteroid
use, n (%)
15 (40.5) 21 (53.8) 18 (48.6) 17 (47.2) 15 (41.7) 10 (28.6)
Baseline daily
corticosteroid dose,a
mg, median (range)
20.0 (5–45) 20.0 (5–45) 22.5 (10–45) 20.0 (5–45) 20.0 (10–45) 30.0 (10–45)
Prior
immunosuppressants,
n (%)
16 (43.2) 12 (30.8) 12 (32.4) 12 (33.3) 13 (36.1) 16 (45.7)
Prior TNF antagonist, n (%)
0 2 (5.4) 2 (5.1) 1 (2.7) 2 (5.6) 0 2 (5.7)
1 15 (40.5) 17 (43.6) 12 (32.4) 6 (16.7) 10 (27.8) 10 (28.6)
2 15 (40.51) 16 (41.0) 20 (54.1) 24 (66.7) 15 (41.7) 16 (45.7)
3 5 (13.5) 4 (10.3) 4 (10.8) 4 (11.1) 9 (25.0) 7 (20.0)
Prior non-TNF antagonist
biologics, n (%)
14 (37.8) 15 (38.5) 19 (51.4) 15 (41.7) 16 (44.4) 14 (40.0)
BID, twice daily; QD, once daily.
aPrednisone equivalent.
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CLINICAL
ATcomparison and modeling techniques to evaluate a dose-
response signal and estimate target effective doses in phase 2
studies.17 Five prespecified potential candidate models were
considered: linear, Emax, exponential, logistic, and sigmoid Emax.
Assuming clinical remission and endoscopic remission rates of
12% in the placebo arm and a maximum of 35% in at least 1 of
the upadacitinib twice daily treatment arms compared with
placebo at week 12/16, 35 patients per treatment arm had at
least 80% power to detect a 1-sided 5% level of significance (or
2-sided 10% level) for the presence of a dose-response curve.
The prespecified models did not include the 24-mg once daily
arm in the dose-ranging evaluations.
During the induction period, efficacy endpoints were
analyzed for the modified intention-to-treat population, defined
as all randomized patients who received at least 1 dose of the
study drug. For selected endpoints (clinical remission 1.5/1.0FLA 5.6.0 DTD  YGAST63194_prooand clinical remission 2.8/1.0 at week 16, endoscopic remission
and endoscopic response 50% at week 12/16), the overall
dose-response relationships between multiple upadacitinib
doses and placebo were tested by MCP-Mod (Supplementary
Table 3).
Coprimary endpoints and categorical secondary endpoints
between each of the upadacitinib dose groups and placebo
were also compared using the Cochran-Mantel-Haenszel (CMH)
test, stratified by baseline SES-CD (SES-CD <15 and 15). No
prespecified primary contrast or prespecified dose-placebo
testing sequences were performed. The CMH-based 2-sided
95% confidence intervals (CIs) for the difference in pro-
portions between arms were calculated. Comparisons of mean
change from baseline in IBDQ between each upadacitinib dose
and placebo were analyzed using a mixed model for repeated
measures with treatment, baseline SES-CD (SES-CD <15 andf  2 May 2020  5:03 pm  ce
476
477
478
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Table 2.MCP-Mod Dose-Response Modeling
Outcome Rate, %
Models,
2-sided P value
Clinical remission 1.5/1.0 Placebo: 11
3 mg BID: 13
6 mg BID: 27
12 mg BID: 11
24 mg BID: 22
Exponential: .6856
Linear: .6312
Emax: .4152
SigEmax: .5012
Logistic: .6464
Quadratic: .5540
Endoscopic remission Placebo: 0
3 mg BID: 10
6 mg BID: 8
12 mg BID: 8
24 mg BID: 22
Exponential: .0406
Linear: .0439
Emax: .0570
SigEmax: .0912
Logistic: .1815
Quadratic: .1279
Clinical remission 2.8/1.0 Placebo: 12
3 mg BID: 16
6 mg BID: 30
12 mg BID: 27
24 mg BID: 37
Exponential: .1567
Linear: .0678
Emax: .0344
SigEmax: .0380
Logistic: .0560
Quadratic: .0484
Endoscopic response 50% Placebo: 3
3 mg BID: 13
6 mg BID: 21
12 mg BID: 29
24 mg BID: 33
Exponential: .1605
Linear: .0369
Emax: .0069
SigEmax: .0099
Logistic: .0150
Quadratic: .0084
NOTE. MCP-Mod was usedQ33 to test a predefined group of
candidates’ dose-response curves against a flat dose-
response curve to best characterize the dose-response
relationship. The 6 prespecified candidate models were
linear, Emax, exponential, logistic, sigEmax, and quadratic. The
MCP-Mod method was implemented to identify the signifi-
cant models among the prespecified models while controlling
the overall type 1 error in the strong sense at a 2-sided sig-
nificance level of .10.
ADDPLANQ34 software, version 3.1.8, was used to evaluate
different dose-response models and to make dose
recommendations.
Models were applied to characterize the dose-response for
upadacitinib for the 2 coprimary endpoints of clinical 1.5/1.0
and endoscopic remission and 2 exploratory endpoints of
clinical remission 2.8/1.0 and endoscopic response 50%. All
statistical significances were tested at the 2-sided 10% level.
BID, twice daily. Emax, maximum effect; SigEmax, sigmoid
Emax.
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covariates.
During the maintenance period, the efficacy analyses
included patients who received upadacitinib during the induc-
tion period in 2 modified intent-to-treat (mITT) sub-
populations: clinical responders (patients who achieved clinical
response at week 16) and responders (patients who achieved
both clinical response at week 16 and endoscopic response
25% at week 12/16).
Comparisons between the 6- and 12-mg twice daily and 24-
mg once daily doses of upadacitinib with the 3-mg twice daily
dose were performed using the chi-squared test (or Fisher’s
exact test if 20% of the cells had expected cell count of <5)
for categorical efficacy endpoints and analysis of covarianceFLA 5.6.0 DTD  YGAST63194_proowith treatment as a factor and value at induction baseline as a
covariate for mean change from baseline in hs-CRP and fecal
calprotectin, using last observation carried forward. Missing
values and data for patients who prematurely discontinued or
who initiated or received corticosteroids at a dose higher than
at baseline were imputed as nonresponders. Nonresponder
imputation was also applied to patients with inadequate
response and who received open-label rescue treatment during
the maintenance period.
All tests of statistical significance were at the 2-sided 10%
level of significance (P  .1), which is frequently used in phase
2b trials, where the focus of the study is to facilitate the dose
selection for future phase 3 trials.18 No multiplicity adjust-
ments were applied for this dose-ranging study on key sec-
ondary endpoints. Upadacitinib pharmacokinetic parameters
were estimated using a nonlinear mixed-effects population
modeling approach.
Safety analyses included all randomized patients who
received at least 1 dose of upadacitinib and were summarized
by study arm and study period and presented as proportions of
patients. All analyses were performed with SAS software,
version 9.4 (SAS Institute Inc, Cary, NC). This trial was regis-
tered with ClinicalTrials.gov, number NCT02365649.
All authors had access to study data, reviewed and
approved the final report, and take full responsibility for the
accuracy of the data and statistical analysis. The first and cor-
responding authors had final responsibility for the decision to
submit for publication.599Results
The study was conducted between March 17, 2015,
and August 3, 2017. Of the 370 patients who were
screened, 150 were excluded (41%); the most common
reason for screening failure was not meeting inclusion
criteria (n ¼ 123/150; 82%), namely, the SES-CD criterion,
baseline CDAI below 220, and abnormal laboratory values
at screening. The remaining 220 patients were random-
ized to receive placebo (n ¼ 37), or upadacitinib 3 mg (n ¼
39), 6 mg (n ¼ 37), 12 mg (n ¼ 36), or 24 mg twice daily
(n ¼ 36), or 24 mg once daily (n ¼ 35) (Supplementary
Figure 2). Overall, 180 patients (82%) completed the in-
duction period and were re-randomized for the mainte-
nance period to receive upadacitinib 3 mg (n ¼ 61), 6 mg
(n ¼ 23), or 12 mg twice daily (n ¼ 59) or 24 mg once
daily (n ¼ 37) (Supplementary Figure 2). Of these, 153
patients received upadacitinib in the induction period, ; 94
were mITT clinical responders and 54 were mITT re-
sponders at week 16. The most common primary reasons
for discontinuations were AEs (upadacitinib, 14/183
[8%]; placebo, 3/37 [8%]) and lack of efficacy (upadaci-
tinib, 6/183 [3%]; placebo, 3/37 [8%]) during the in-
duction period and lack of efficacy (27/180 [15%]) and
AEs (14/180 [8%]) during the maintenance period
(Supplementary Figure 2).
At baseline, the median disease duration was 9.6 years,
and 96% (211/220) of patients had an inadequate response
or intolerance to 1 TNF antagonist; 64% of patients (141/
220) had been exposed to 2 TNF antagonists and 42%
(93/220) to non-TNF antagonist biologics (Table 1).f  2 May 2020  5:03 pm  ce
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Figure 1. Coprimary endpoints of (A) clinical remission 1.5/1.0 and (B) endoscopic remission at induction period week 12/16 in
all patients and maintenance period week 52 in responders and clinical responders. Nonresponder imputation. Statistical
significance: †P < .1, *P < .05, **P < .01 vs placebo during the induction period and vs 3 mg twice daily during the main-
tenance period. Clinical responders were defined as patients who achieved clinical response at week 16, and responders were
defined as patients who achieved both clinical response and endoscopic response 25% at week 16. BID, twice daily; PBO,
placebo; QD, once daily.
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For the coprimary endpoint of clinical remission 1.5/1.0,
the overall dose-response relationship between upadaciti-
nib and placebo was not significant by MCP-Mod in any of
the prespecified candidate models (Table 2). At week 16,
clinical remission 1.5/1.0 occurred in 13% (5/39), 27%
(10/37; P < .1), 11% (4/36), 22% (8/36), and 14% (5/35)
of patients receiving upadacitinib 3, 6, 12, and 24 mg twice
daily and 24 mg once daily, respectively, compared with
11% (4/37) of patients receiving placebo (Figure 1A). CMH-
adjusted risk differences (95% CIs) for clinical remission
were 2.5 (12.3 to 17.3) for the 3 mg twice daily, 16.2
(2.0 to 34.3) for the 6 mg twice daily, 0.5 (14.1 to 15.0)
for the 12 mg twice daily, 11.2 (6.1 to 28.5) for the 24 mg
twice daily, and 4.1 (11.5 to 19.6) for the 24 mg once daily
arms.
For endoscopic remission, the overall dose-response
relationship between upadacitinib and placebo was
detected by MCP-Mod in 4 of the 6 prespecified
candidate models (exponential [P ¼ .04], linear [P ¼
.04], Emax [P ¼ .06] and sigmoid Emax [P ¼ .09])
(Table 2). At week 12/16, endoscopic remissionFLA 5.6.0 DTD  YGAST63194_proo
719occurred in 10% (4/39; P < .1), 8% (3/37), 8% (3/36;
P < .1), 22% (8/36; P < .01), and 14% (5/35; P < .05)
of patients receiving upadacitinib 3 mg, 6 mg, 12 mg,
and 24 mg twice daily and 24 mg once daily, respec-
tively, compared with 0% (0/37) of patients receiving
placebo (Figure 1B). CMH-adjusted risk differences
(95% CI) were 9.9 (0.3 to 20.1) for the 3 mg twice
daily, 7.4 (1.6 to 16.4) for the 6 mg twice daily, 7.7
(1.5 to 16.8) for the 12 mg twice daily, 21.0 (6.8 to
35.2) for the 24 mg twice daily, and 13.6 (1.8 to 25.5)
for the 24 mg once daily arms.
Secondary and Exploratory Efficacy Endpoints
Induction Period. Using the exploratory endpoints,
dose-response relationships with upadacitinib twice daily
doses were observed for clinical remission 2.8/1.0 and
endoscopic response 50% per MCP-Mod in 5 of the 6
prespecified candidate models (all except the exponential
model) (Table 2). More patients achieved clinical remis-
sion 2.8/1.0 at week 16 with 6 mg twice daily (30% [10/
33]; P < .1) and 24 mg twice daily (37% [11/30]; P < .05)
compared with placebo (12% [4/33]) (Figure 2A).f  2 May 2020  5:03 pm  ce
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Figure 2. Secondary endpoints of (A) clinical remission 2.8/1.0, (B) endoscopic response 50%, (C) CDAI <150, and (D)
corticosteroid-free CDAI <150 at induction period week 12/16 in all patients and maintenance period week 52 in responders
and clinical responders. Nonresponder imputation. Statistical significance: †P < .1, *P <.05, **P < .01, ***P < .001 vs placebo
during the induction period and vs 3 mg twice daily during the maintenance period. Clinical responders were defined as
patients who achieved clinical response at week 16, and responders were defined as patients who achieved both clinical
response and endoscopic response 25% at week 16. BID, twice daily; PBO, placebo; QD, once daily.
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Table 3.Summary of Additional Key Secondary Endpoints During the Induction Period
Endpoints
Placebo
n ¼ 37
Upadacitinib
3 mg BID
n ¼ 39
6 mg BID
n ¼ 37
12 mg BID
n ¼ 36
24 mg BID
n ¼ 36
24 mg QD
n ¼ 35
Secondary endpoint
Clinical remission 1.5/1.0 at week 12, n (%) 4 (10.8) 4 (10.3) 11 (29.7)a 5 (13.9) 9 (25.0) 3 (8.6)
Clinical remission 2.8/1.0 at week 12, n (%) 3 (9.1)
(n ¼ 33)
6 (15.8)
(n ¼ 38)
9 (27.3)a
(n ¼ 33)
10 (29.4)b
(n ¼ 34)
10 (33.3)b
(n ¼ 30)
4 (12.5)
(n ¼ 32)
Clinical response at week 16, n (%) 12 (32.4) 17 (43.6) 21 (56.8)a 17 (47.2) 22 (61.1)b 17 (48.6)
CR-70 at week 16, n (%) 13 (35.1) 18 (46.2) 20 (54.1) 16 (44.4) 22 (61.1)b 17 (48.6)
Endoscopic response 25% at week 12/16, n (%) 5 (13.5) 9 (23.1) 16 (43.2)c 13 (36.1)a 18 (50.0)d 17 (48.6)d
Remission at week 16, n (%) 0 1 (2.6) 2 (5.4) 1 (2.8) 3 (8.3)a 2 (5.7)
Response at week 16, n (%) 1 (2.7) 6 (15.4)b 12 (32.4)c 10 (27.8)c 14 (38.9)d 12 (34.3)d
Clinical remission 1.5/1.0 in patients with SF 2.5 and AP 2.0 at
baseline, n (%)
1 (7.1)
n ¼ 14
3 (17.6)
n ¼ 17
3 (18.8)
n ¼ 16
3 (16.7)
n ¼ 18
3 (25.0)
n ¼ 12
2 (11.1)
n ¼ 18
Clinical remission 1.5/1.0 in patients with isolated ileal disease, n (%) 0
n ¼ 9
2 (20.0)
n ¼ 10
1 (16.7)
n ¼ 6
1 (20.0)
n ¼ 5
0
n ¼ 6
2 (20.0)
n ¼ 10
Endoscopic remission among patients with no missing individual
variables, n (%)
0
n ¼ 15
4 (14.3)
n ¼ 28
2 (8.7)
n ¼ 23
3 (13.0)
n ¼ 23
8 (30.8)b
n ¼ 26
5 (22.7)a
n ¼ 22
Change from baseline in hs-CRP at week 16, mean ± SD (median) –0.1 ± 12.0
(0.0)
–3.0 ± 19.6
(0.0)
–3.9 ± 19.5 (–4.6) –6.1 ± 27.0
(–0.3)
–14.8 ± 26.4b
(–3.2)
–2.7 ± 13.7
(–0.2)
Change from baseline
in fecal calprotectin at week 16, mean ± SD (median)
–128.9 ±
373.5
(0.0)
–534.5 ± 3279.2
(91.0)
–429.4 ± 2505.2
(–233.0)
–475.1 ± 2668.9
(–134.0)
–828.7 ± 986.1
(–671.5)
–698.4 ±
2228.9
(0.0)
Change in IBDQ from baseline at week 16, mean ± SD (median) 14.5 ± 29.2
(2.0)
24.6 ± 43.0
(17.0)
41.8 ± 47.0c
(38.0)
32.1 ± 38.6a
(22.0)
44.4 ± 40.1c
(37.0)
22.5 ± 27.8
(18.5)
Placebo
n ¼ 15
Upadacitinib
3 mg BID
n ¼ 21
6 mg BID
n ¼ 18
12 mg BID
n ¼ 17
24 mg BID
n ¼ 15
24 mg QD
n ¼ 10
Secondary endpoints in patients with corticosteroid-use at
baseline, n Q35(%)
Corticosteroid-free clinical remission 1.5/1.0 at week 16 0 3 (14.3) 4 (22.2) 2 (11.8) 5 (33.3)b 1 (10.0)
Corticosteroid-free endoscopic remission at week 16 0 0 2 (11.1) 1 (5.9) 3 (20.0) 1 (10.0)
Corticosteroid-free remission at week 16 0 0 1 (5.6) 1 (5.9) 2 (13.3) 0
NOTE. Clinical remission 1.5/1.0 was defined as average daily very soft/liquid SF 1.5 and average daily AP score 1, without worsening from baseline. Clinical remission
2.8/1.0 was defined as average daily very soft/liquid SF 2.8 and average daily AP score 1, neither worse than baseline, among patients with baseline average daily very
soft/liquid SF 4.0 or average daily AP score 2.0. Clinical response was defined as 30% reduction from baseline in average daily very soft/liquid SR and/or average
daily AP score, neither worse than baseline. CR-70 was defined as decrease in CDAI 70 points from baseline. Remission was defined as combined clinical remission 1.5/
1.0 and endoscopic remission, and response was defined as combined clinical response and endoscopic response 25%.
BID, twice daily; QD, once daily.
aSignificance Q36vs placebo at P < .1.
bSignificance vs placebo at P < .05.
cSignificance vs placebo at P < .01.
dSignificance vs placebo at P < .001.
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Figure 3. (A) IBDQ remission and (B) IBDQ response at induction period week 12/16 in all patients and maintenance period
week 52 in responders and clinical responders. IBDQ remission was defined as IBDQ 170. IBDQ response was defined as
increase in IBDQ 16 points from baseline. Nonresponder imputation. Statistical significance: †P < .1, *P < .05, **P < .01 vs
placebo during the induction period and vs 3 mg twice daily during the maintenance period. Clinical responders were defined
as patients who achieved clinical response at week 16, and responders were defined as patients who achieved both clinical
response and endoscopic response 25% at week 16. BID, twice daily; PBO, placebo; QD, once daily.
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higher proportion of patients receiving 6 mg (19% [7/37];
P < .05), 12 mg (25% [9/36]; P < .01) and 24 mg twice
daily (36% [13/36]; P < .001) and 24 mg once daily (26%
[9/35]; P < .01) compared with placebo (3% [1/37])
(Figure 2B).
At week 16, 20%–39% of patients receiving upadacitinib
achieved CDAI <150 vs 16% receiving placebo (Figure 2C);
a similar trend was observed for other secondary endpoints
at week 16 (Table 3). Efficacy was observed as early as
week 2 and maintained to week 16 with upadacitinib
(Supplementary Figure 3). Endoscopic remission was
nonsignificantly higher in the 24 mg twice daily group
compared with the placebo group at week 12 (data not
shown).
Among the subgroup of patients receiving corticoste-
roids at baseline, significantly more patients were able to
discontinue their corticosteroid and achieve a CDAI <150 at
week 16 with upadacitinib 12 mg (41% [7/17]) and 24 mg
twice daily (33% [5/15]) compared with placebo (0% [0/
15]; both P < .05) (Figure 2D). The proportion of patients
with corticosteroid-free clinical remission 1.5/1.0 was
significantly higher with upadacitinib 24 mg twice daily
(33%) vs placebo (0%; P < .05) at week 16 (Table 3).FLA 5.6.0 DTD  YGAST63194_prooThe mean change (reduction) from baseline to week 16
in hs-CRP was significant for the 24 mg twice daily arm
(–14.8) vs placebo (–0.1; P < .05); changes in fecal calpro-
tectin did not reach significance vs placebo (Table 3).
Maintenance Period. At week 52, among mITT re-
sponders and clinical responders, the percentage of patients
with clinical remission 1.5/1.0 (63% and 41%) and endo-
scopic remission (38% and 24%) (Figure 1A and B) and
clinical remission 2.8/1.0 (73% and 52%), endoscopic
response 50% (69% and 45%), and CDAI <150 (69% and
55%) (Figure 2A–C), respectively, was highest among pa-
tients receiving 12 mg twice daily compared with the other
dose groups, but these differences were not significant.
Other secondary endpoints showed similar trends
(Supplementary Table 3). At week 52, the percentage of
patients who achieved corticosteroid-free efficacy endpoints
increased with increasing twice daily doses (Figure 2D and
Supplementary Table 3).
Quality of Life. A significantly greater proportion of
patients achieved IBDQ remission with upadacitinib 6 mg,
12 mg, and 24 mg twice daily doses and IBDQ response with
upadacitinib 3 mg, 6 mg, 12 mg, and 24 mg twice daily and
24 mg once daily doses at week 16 compared with placebo
(all P < .05) (Figure 3). Mean improvements from baselinef  2 May 2020  5:03 pm  ce
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Table 4.Treatment-Emergent AEs During the Induction and Maintenance Periods, n (%)
AE
Placebo
n ¼ 37
Induction Period Maintenance Period
Upadacitinib Upadacitinib
3 mg BID
n ¼ 39
6 mg BID
n ¼ 37
12 mg BID
n ¼ 36
24 mg BID
n ¼ 36
24 mg QD
n ¼ 35
3 mg BID
n ¼ 60a
6 mg BID
n ¼ 23
12 mg BID
n ¼ 59
24 mg QD
n ¼ 36a
Any AE 27 (73.0) 34 (87.2) 29 (78.4) 29 (80.6) 30 (83.3) 29 (82.9) 45 (75.0) 14 (60.9) 43 (72.9) 23 (63.9)
Any serious AE 2 (5.4) 5 (12.8) 2 (5.4) 10 (27.8) 3 (8.3) 7 (20.0) 15 (25.0) 2 (8.7) 5 (8.5) 4 (11.1)
Any AE leading to
discontinuation
5 (13.5) 4 (10.3) 1 (2.7) 9 (25.0) 3 (8.3) 4 (11.4) 6 (10.0) 0 5 (8.5) 3 (8.3)
Infectionsb 12 (32.4) 16 (41.0) 19 (51.4) 16 (44.4) 20 (55.6) 12 (34.3) 22 (36.7) 6 (26.1) 22 (37.3) 10 (27.8)
Serious infections 0 3 (7.7) 0 3 (8.3) 1 (2.8) 2 (5.7) 5 (8.3) 0 1 (1.7) 0
Herpes zosterc 0 0 0 0 1 (2.8) 0 0 0 1 (1.7) 1 (2.8)
Tuberculosis 0 0 0 0 0 0 0 0 0 0
Opportunistic infectiond 0 0 0 0 0 1 (2.9) 1 (1.7) 0 0 0
Intestinal perforations 0 0 0 0 1 (2.8) 1 (2.9) 0 0 0 0
Malignancy, excluding
nonmelanoma skin
cancer
0 0 0 0 0 0 0 0 2 (3.4) 0
Nonmelanoma skin cancer 0 0 0 0 1 (2.8) 0 0 0 0 0
Adjudicated cardiovascular
events
0 0 0 1 (2.8) 0 0 1 (1.7) 0 0 0
Deaths 0 0 0 0 0 0 0 0 0 0
BID, twice daily; QD, once daily.
aTwo patients did not receive upadacitinib during the maintenance period and were not included in the safety analysis set.
bSerious infections during the induction period included 4 patients with sepsis (1 patient each receiving 3, 12, and 24 mg BID and 24 mg QD), 2 patients with urinary tract
infection (1 patient each receiving 12 mg BID and 24 mg QD), and 1 patient each with Escherichia coli bacteremia associated with mesenteric vein thrombophlebitis (3 mg
BID), subcutaneous (gluteal) abscess (3 mg BID), and rectal abscess (12 mg BID); of these, 3 events (sepsis, rectal abscess, and subcutaneous abscess) led to
discontinuation, and 3 events (urinary tract infection, thrombophlebitis, and sepsis) were among patients with baseline corticosteroid use. During the maintenance period,
there were 1 event each of abdominal abscess, anal abscess, cellulitis, influenza, and sepsis in the 3 mg BID group and 1 event of abdominal abscess in the 12 mg BID
group; of these, 2 events (abdominal abscess and influenza) led to discontinuation, and 1 event (abdominal abscess) was in a patient with baseline corticosteroid use.
Three patients with serious infections during the study were receiving concomitant mesalazine.
cDuring the induction period, the Q37event was of moderate severity in 2 contiguous dermatomes; during the maintenance period, 1 event was of moderate severity in 1
dermatome with the 12-mg BID dose and 1 was of mild severity in 2 contiguous dermatomes with the 24-mg QD dose.
dOne patient receiving 24 mg QD had a nonserious opportunistic infection of esophageal candidiasis of moderate severity during the induction period; 1 patient in the 3 mg
BID group had a nonserious oral candidiasis event during the maintenance period.
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ATto week 16 in IBDQ were significantly greater in patients
receiving upadacitinib 6 mg and 24 mg twice daily
compared with those receiving placebo (both P < .01)
(Table 3). During the maintenance period, a significantly
greater proportion of responders and clinical responders
receiving upadacitinib 6 mg twice daily and 12 mg twice
daily vs 3 mg twice daily achieved IBDQ response at week
52 (all P < .05) (Figure 3). The improvement from baseline
to week 52 in IBDQ was highest with the 12-mg twice daily
dose among responders and clinical responders, but these
improvements were not significant vs 3 mg twice daily
(Supplementary Table 3).
Pharmacokinetics
Upadacitinib average plasma concentration during a
dosing interval increased proportionally with increasing
dose (Supplementary Figure 4). As expected, the upadaci-
tinib minimum concentration with the 24-mg once daily
dose was significantly lower than with the 12-mg twice
daily dose and was comparable to the 3-mg twice daily dose
(Supplementary Figure 4). During the maintenance period,
the observed upadacitinib plasma concentrations were
consistent with upadacitinib concentrations during the in-
duction period for the respective doses.
Safety
During the induction period, higher incidences of some
AEs were observed at higher upadacitinib doses (>12 mg
twice daily ) (Table 4). The majority of the AEs were
assessed by the investigator as mild or moderate in severity.
The incidence of serious AEs varied from 2 (5%) to 10
(28%) across arms, with the highest incidence in the 12-mg
twice daily arm. The most frequently reported AEs occur-
ring in 5% of patients receiving upadacitinib were head-
ache, worsening of CD, AP, fatigue, upper respiratory tract
infection, urinary tract infection, nausea, vomiting, and acne.
During the induction period, 9 patients receiving upadaci-
tinib developed serious infections (Table 4). During the
maintenance period, 6 serious infections were observed, of
which 5 were in patients receiving upadacitinib 3 mg twice
daily and 1 in patient receiving 12 mg twice daily (Table 4).
During the induction period, 1 patient receiving upadaciti-
nib 24 mg twice daily had a nonserious herpes zoster event,
and 2 patients experienced herpes zoster events during the
maintenance period. Each event resolved with antiviral
treatment (Table 4). All other infections resolved, and none
of the events led to discontinuation. No deaths occurred
during the study.
During the induction period, 1 nonserious event of
nonmelanoma skin cancer was reported in a patient who
received upadacitinib 24 mg twice daily and had prior
exposure to azathioprine. During the maintenance period, 2
malignancies were reported (Table 4). Hodgkin’s disease
was reported in a 29-year-old male patient who received 6
mg twice daily induction treatment for 16 weeks followed
by12 mg twice daily for 36 weeks; this patient had a family
history of non-Hodgkin’s lymphoma (mother) and prior
exposure to 6-mercaptopurine, adalimumab, infliximab,FLA 5.6.0 DTD  YGAST63194_proovedolizumab, and natalizumab. A malignant neoplasm of the
thymus was reported in a 62-year-old male patient who
received 24 mg once daily induction treatment for 16
weeks, followed by 12 mg twice daily for 13 weeks; this
patient had no family history of malignancy or prior expo-
sure to 6-mercaptopurine, azathioprine, methotrexate,
infliximab, and vedolizumab.
A 67-year-old male receiving 12 mg twice daily with a
history of diabetes mellitus, smoking, and family history of
myocardial infarction (MI) had an acute MI during the in-
duction period. This event was assessed as severe and led to
discontinuation of the study drug. During the maintenance
period, a 55-year-old male with history of obesity, hyper-
tension, diabetes mellitus, gout, and gastroesophageal reflux
disease receiving 3 mg twice daily had a pneumonia aspi-
ration adjudicated as an MI.
During the induction period, 2 acute, serious intestinal
perforations with associated serious infections that required
surgical intervention were reported, and both occurred in
areas of active intestinal inflammation of CD in patients with
worsening of disease being treated with upadacitinib and
corticosteroids at baseline (24 mg once daily, event on day
36; 24 mg twice daily, event on day 41; no colonoscopy was
performed near these events). No intestinal perforations
occurred during the maintenance period. One patient
receiving 3 mg twice daily developed a mesenteric vein
thrombophlebitis during the induction period. No events of
deep vein thrombosis or pulmonary embolism were
observed.
No clinically meaningful changes from baseline in mean
hemoglobin, leukocytes, neutrophils, transaminases, and
creatinine concentrations were observed across all treat-
ment arms by week 16 (Supplementary Table 4) or week 52
(Supplementary Table 5). Decreases in platelet counts were
observed at week 16 in the upadacitinib 24 mg once daily
group compared with placebo (P < .1). One patient in the 24
mg twice daily group had a transient grade 4 decrease (63
g/L) in hemoglobin after a total proctocolectomy. Two pa-
tients receiving 24 mg once daily discontinued the study
because of nonserious anemia (each of mild and moderate
severity). Four nonserious events of lymphocyte count
decrease were reported, 1 each in the upadacitinib 12
(grade 1) and 24 mg twice daily (grade 3) arms during the
induction period and 1 each in the 3 (grade 4) and 6 mg
twice daily (grade 3) arms during the maintenance period;
none of these led to discontinuation of the study drug. Sig-
nificant elevations in total, low-density, and high-density
cholesterol and creatinine phosphokinase (CPK) levels and
decreases in triglyceride levels were observed in the upa-
dacitinib 24 mg twice daily arm compared with the placebo
group at week 16; total and low-density cholesterol levels
were also significantly elevated in the 12 mg twice daily
group vs placebo (Supplementary Table 4). Nonsignificant
differences in laboratory values were observed between
dose groups at week 52 (Supplementary Table 5). During
the study, 15 AEs of CPK elevation were reported, all of
which were of mild to moderate severity and were asymp-
tomatic. One patient in the 12 mg twice daily arm had a
>10-fold elevation in CPK levels from the upper limit off  2 May 2020  5:03 pm  ce
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ATnormal with a concurrent acute event of bronchitis. No
patients had rhabdomyolysis or discontinued the study drug
because of increased CPK.25
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CELEST was the first study to evaluate the efficacy,
safety, pharmacokinetics, and dose-response of upadacitinib
immediate-release formulation in patients with moderate to
severe CD and refractory to TNF antagonist therapy using
PRO-based clinical and endoscopic endpoints. The results of
the induction period showed that the 3-mg, 12-mg, and 24-
mg twice daily and 24-mg once daily upadacitinib doses
were superior to placebo for endoscopic remission with
significant dose-response relationships and, separately, that
the 6-mg twice daily dose was superior to placebo for
clinical remission 1.5/1.0 at the P < .10 level. Furthermore,
maintenance treatment over 36 weeks was associated with
continued clinical and endoscopic responses as well as de-
creases in markers of inflammation in patients who
responded to the 16-week induction regimen.
During the induction period, the 24-mg twice daily dose
exhibited the most consistent association with meaningful
improvements for multiple clinical and endoscopic end-
points at weeks 12 or 16 (including endoscopic remission,
endoscopic response 25%, clinical response, CR-70, com-
bined clinical and endoscopic remission and response,
corticosteroid-free clinical remission, and corticosteroid-free
CDAI <150). Decreases in serum hs-CRP concentrations
were observed, indicating a systemic anti-inflammatory
effect that was consistent with the clinical and endoscopic
findings. Furthermore, upadacitinib was also associated with
improvements in quality of life, based on IBDQ, observed
as early as week 8, further improved by week 16, and
accompanied by achievement of IBDQ remission at the end of
the induction period.
During the maintenance period, patients receiving the
12-mg twice daily dose had the highest, although nonsig-
nificant, responses compared with the other upadacitinib
doses. More than 63% of responders receiving 12 mg twice
daily upadacitinib achieved most clinical, endoscopic, and
quality of life endpoints at week 52. Among clinical re-
sponders, 41% of patients achieved the same endpoints at
week 52. Furthermore, serum hs-CRP concentrations
continued to decrease from baseline, indicating that the
anti-inflammatory effect was maintained. Overall, these re-
sults suggest that in patients with active CD who for whom
previous treatments have failed, continued use of JAK in-
hibitor therapy may induce and preserve remission over
extended periods of time.
The identification of specific PRO endpoints that are
relevant for patients with CD is of high interest to better
evaluate individual patients with different levels of disease
severity. We assessed 2 exploratory clinical and endoscopic
endpoints in this study (clinical remission 2.8/1.0 and
endoscopic response 50%) and observed a significant dose-
response relationship in 5 of the 6 models used. These
additional endpoints were determined from a post hocFLA 5.6.0 DTD  YGAST63194_proo
1439analysis of a large data set of patients with moderately to
severely active CD receiving adalimumab15 and tested here
with the intention of choosing clinically relevant PROs for
use in future clinical trials. The more stringent clinical
remission 1.5/1.0 definition, which was initially chosen as
the coprimary endpoint for CELEST, was proposed by
Khanna et al14 and developed in patients with mild to
moderate CD without exposure to TNF antagonists. Our
results are consistent with the adalimumab analysis15 and
suggest that the clinical remission 1.5/1.0 endpoint is
infrequently achieved in patients with moderate to severe,
long-standing CD Qthat was already refractory to drugs with
known efficacy such as TNF antagonists, vedolizumab, and
ustekinumab. The most statistically efficient measurement
of endoscopic healing has not been established. In this
study, both endoscopic remission and response 50% were
more common in the patients receiving upadacitinib, but
there was a more linear dose-response relationship evident
with the endoscopic response 50%. These results indicate
that different thresholds for the coprimary endpoints are
useful in assessing efficacy in this patient population,
especially because clearer dose-responses were observed
with upadacitinib, whereas placebo rates essentially
remained unchanged.
Nearly half of the patients enrolled in CELEST (44% [96/
220]) were taking oral corticosteroids at baseline and un-
derwent a mandatory taper starting at week 2. The intent
was to determine if induction treatment with upadacitinib
could facilitate earlier corticosteroid taper. Our results
showed that a greater proportion of patients receiving
upadacitinib were able to discontinue corticosteroids and
achieve clinical remission 1.5/1.0 and CDAI <150 compared
with placebo during the induction period. Although this
could be considered an aggressive approach in this popu-
lation with treatment-refractory disease Q, it further differ-
entiated active treatment with upadacitinib from placebo.
To our knowledge, this is the first time a JAK inhibitor or
any therapy other than methotrexate has been shown to be
effective in achieving corticosteroid-free clinical remission
in an induction trial of CD.19
Upadacitinib plasma exposures with the twice daily
doses of upadacitinib in patients with CD were consistent
with the previously characterized upadacitinib pharma-
cokinetics in healthy participants and in patients with
RA.20–22 Furthermore, there were no time-dependent
changes in upadacitinib plasma exposures during the
study, consistent with the well-characterized pharmaco-
kinetic profile of upadacitinib. In 2 dose-ranging studies of
patients with RA, upadacitinib 6 and 12 mg twice daily
appeared to maximize efficacy.23,24 In contrast, in CELEST,
the 24-mg twice daily induction dose was generally more
effective, particularly for the endoscopic endpoints, hs-
CRP, and quality of life measures in patients with
moderately to severely active CD. The 24-mg once daily
dose resulted in comparable average plasma concentra-
tions to the 12-mg twice daily dose but significantly lower
upadacitinib trough plasma concentrations than the 12-mg
twice daily dose, which may explain the suboptimal effi-
cacy noted for 24 mg once daily in numerous clinicalf  2 May 2020  5:03 pm  ce
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ATendpoints. This suggests the importance of maintaining
exposure during the entire dosing interval. For this
reason, an extended-release once daily formulation of
upadacitinib has been developed to enhance patients’
convenience and is currently being evaluated in multiple
trials for various treatment indications.25
The AEs reported in this study were consistent with
those previously observed in clinical trials with JAK in-
hibitors in patients with moderately to severely active in-
flammatory bowel disease8,9,26 and RA.23,24,27–31 No fatal
AEs were observed during the study. Overall, the incidence
of serious AEs and serious infections was highest with the
12 mg twice daily and 3 mg twice daily upadacitinib dose
during the induction and maintenance periods, respectively.
Infections and viral reactivation have been reported with
JAK inhibitors previously,27,28 and an increased risk of
herpes zoster was reported with tofacitinib 10 mg twice
daily.32 An estimation of the risk and incidence of infections
with upadacitinib exposure warrants additional evaluation
in larger and long-term studies.
Two intestinal perforations were observed during the
induction period and none during maintenance period of
the CELEST study. Intestinal perforations were initially
reported with tocilizumab33 and tofacitinib29 and may be
related to an effect on IL-6, which plays an important
function in the intestinal barrier. Additional identified
risk factors for intestinal perforations include age, cur-
rent and cumulative use of corticosteroids and nonste-
roidal anti-inflammatory drugs, and complicated
diverticular disease.29,34 In CELEST, the 2 intestinal
perforation events occurred in areas of active intestinal
inflammation of CD in patients treated with upadacitinib
and corticosteroids.
Two patients with cardiovascular risk factors had MI
events, and 1 patient had a mesenteric vein thrombophle-
bitis, a rare complication of IBD. No events of deep vein
thrombosis or pulmonary embolism were observed; how-
ever, this phase 2 study was limited in its ability to detect
these rare events. Dose-dependent, meaningful increases in
lipids and CPK were also observed. Similar effects were
reported with drugs of the same class in prior trials of pa-
tients with CD,9 ulcerative colitis,21 and RA35; the mecha-
nisms are currently unknown.
This phase 2 study provided long-term, double-blind
data for safety and efficacy for the JAK inhibitor class in
patients with CD. Although the sample size was sufficient
to assess dose-response relationships for efficacy end-
points in the induction period, it was inadequate to fully
evaluate some efficacy parameters, particularly more
stringent measures, between individual upadacitinib
doses and placebo or to characterize the safety of upa-
dacitinib, which are typically addressed in a larger phase
3 program. The lack of placebo control during the
maintenance period and small sample size, particularly
for the 6-mg twice daily dose group, were limitations of
this study. The threshold for statistical significance was
set a priori at 0.1 for the purpose of this dose-finding
study, with no multiplicity adjustment for the second-
ary endpoints; therefore, the potential for false positiveFLA 5.6.0 DTD  YGAST63194_proofindings was greater. Also, the stringency of the novel
protocol-specified coprimary endpoints may have
affected the evaluation of upadacitinib therapy. This
study evaluated several other novel clinical and endo-
scopic endpoints based on recent regulatory guidance
and post hoc analyses of existing data from other tri-
als.14,15 Further evaluation is needed to determine if
these endpoints are optimal to differentiate between
effective doses and placebo.
In conclusion, upadacitinib was superior to placebo
primarily in inducing endoscopic improvements in patients
with moderately to severely active long-standing CD and
largely refractory to biologics. Furthermore, after
achievement of response during a 16-week induction
period, maintenance therapy with upadacitinib led to
sustained clinical, endoscopic, and patient-reported bene-
fits. Upadacitinib safety and efficacy in moderately to
severely active CD will be further characterized in the
phase 3 program.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at https://doi.org/10.1053/
j.gastro.2020.01.047.f  2References
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Supplementary Figure 1. CELEST study design. BID, twice
daily; QD, once daily; UPA, upadacitinib.
Supplementary Figure 2. Patient disposition. *Some patients were excluded due to multiple reasons. †Received UPA during
the induction period: 3 mg BID, n ¼ 52 (responders: n ¼ 20; clinical responders, n ¼ 32); 6 mg BID, n ¼ 18 (responders: n ¼ 8;
clinical responders, n ¼ 14); 12 mg BID, n ¼ 50 (responders: n ¼ 16; clinical responders, n ¼ 29); 24 mg QD, n ¼ 33 (re-
sponders: n ¼ 10; clinical responders, n ¼ 19). ‡Completers among those who received UPA during induction period: 3 mg
BID, n ¼ 37; 6 mg BID, n ¼ 16; 12 mg BID, n ¼ 37; 24 mg QD, n ¼ 18. Alt therapy, alternative therapy; BID, twice daily; LOE,
lack of efficacy; Non-compl, noncompliance; QD, once daily; UPA, upadacitinib.
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Figure 3. Efficacy end-
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twice daily; QD, once daily.
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Supplementary Table 1. Inclusion and Exclusion Criteria
Inclusion criteria
1. Male or female 18 and 75 years of age at baseline
2. Diagnosis of ileal, colonic, or ileocolonic CD for 3 months before baseline confirmed by endoscopy during the screening period or
endoscopy performed within 15 days of the screening visit. Appropriate documentation of biopsy results consistent with the diagnosis of
CD, in the assessment of the investigator, must be available
3. Average daily liquid/very soft SF score 2.5 daily or average daily AP score 2.0
4. CDAI score 220 and 450
5. SES-CD 6 (or 4 for patients with disease limited to the ileum), confirmed by a central reader. A video-recorded ileocolonoscopy
performed within 15 days before screening can be used for the local and central reader assessment
6. Patient has inadequately responded to or experienced intolerance to previous treatment with immunomodulators (eg, azathioprine, 6-MP,
MTX) and/or an anti-TNF agent (eg, infliximab, adalimumab, certolizumab pegol). The clinical measures that defined inadequate response
should be based on the physician/investigator clinical assessment. Criteria for inadequate response to or experienced intolerance to
previous treatment with an immunomodulator or anti-TNF agent defined as:
 Signs and symptoms of persistently active disease despite a history of induction regimen with 1 of the following agents:
o At least a consecutive 42-day course of azathioprine, 6-MP, or injectable MTX before baseline, with a stable dose for at least 28 days
before baseline of azathioprine 1.5 mg/kg/d or 6-MP 1 mg/kg/d (rounded to the nearest available tablet or half-tablet formulation
or a documented 6-TGN level of at least 230 pmol/8  108 RBC or higher on the current dosing regimen) or MTX 15 mg/week (SC/
IM), or a dose that is the highest tolerated by the patient (eg, due to leukopenia, elevated liver enzymes, nausea) during that time
o At least 1 6-week induction with infliximab: 5 mg/kg IV, 2 doses at least 2 weeks apart
o At least 1 4-week induction with adalimumab: one 160-mg SC dose (or 80-mg SC dose in approved countries) followed by one 80-mg
SC dose (or 40-mg SC dose in approved countries) followed by one 40-mg dose at least 2 weeks apart
o At least one 4-week induction with certolizumab pegol: 400 mg SC, 2 doses at least 2 weeks apart OR
o Recurrence of symptoms during scheduled maintenance dosing following prior clinical benefit (discontinuation despite clinical benefit
does not qualify) OR
o History of intolerance of at least one TNF antagonist (including, but not limited to, infusion-related reaction, demyelination, congestive
heart failure, and infection)
7. Patient has a negative TB screening assessment result Q38. If the patient has evidence of a latent TB infection, the patient must initiate and
complete a minimum of 2 weeks (or per local guidelines, whichever is longer) of an ongoing TB prophylaxis or have documented
completion of a full course of anti-TB prophylaxis, before baseline
8. A negative serum pregnancy test result Q39for all female patients at the screening visit and a negative urine pregnancy test result for all female
patients of childbearing potential at baseline before the first dose of study drug
9. If female, patient must be either postmenopausal OR permanently surgically sterile OR, for women of childbearing potential, practicing at
least 1 protocol-specified method of birth control that is effective from study day 1 through at least 180 days after the last dose of study
drug
10. Male patients who are sexually active with female partner(s) of childbearing potential must agree from study day 1 through 90 days after
the last dose of study drug to practice the protocol-specified contraception
11. Patient must be able and willing to give written informed consent and to comply with the requirements of this study protocol
12. Patient is judged to be in otherwise good health as determined by the principal investigator based on the results of medical history,
laboratory profile, physical examination, and a 12-lead ECG performed during screening
Exclusion criteria
1. Patient with a current diagnosis of UC, collagenous colitis, or indeterminate colitis
2. Patient with previous exposure to JAK inhibitor (eg, tofacitinib, baricitinib)
3. Patients who discontinued biologic therapy such as infliximab (Remicade Q40), certolizumab (Cimzia), adalimumab (Humira), vedolizumab
(Entyvio), or natalizumab (Tysabri) <8 weeks before baseline. Patients who discontinued ustekinumab (Stelara) <12 weeks before baseline
4. Patient received azathioprine or 6-MP within 10 days of baseline
5. Patient who previously or currently uses oral aminosalicylates or MTX and meets 1 of the following criteria:
 Has not been on stable doses for at least 14 days before baseline; or
 Has discontinued use of aminosalicylates or MTX within 14 days of baseline
6. Patient who previously or currently uses oral corticosteroid and meets 1 of the following criteria:
 Is receiving prednisone or prednisone equivalent >30 mg/day within 7 days of baseline;
 Is receiving budesonide >9 mg/day within 7 days of baseline;
 Has discontinued use of corticosteroid within 7 days of baseline;
 Has not been on stable doses of corticosteroid for at least 7 days before baseline; or
 Has been taking both oral budesonide and oral prednisone (or equivalent) simultaneously
7. Received IV corticosteroids within 14 days before screening or during the screening period
8. Patient on probiotics who has not been on stable dose for at least 14 days before baseline
9. Patient who previously or currently uses CD-related antibiotics and meets 1 of the following criteria:
 Has not been on stable doses for at least 14 days before baseline;
 Has discontinued CD-related antibiotics within 14 days of baseline
10. Patient received cyclosporine, tacrolimus, or mycophenolate mofetil within 30 days before baseline
11. Patient has received therapeutic enema or suppository, other than required for endoscopy, within 7 days before screening and/or during
the screening period
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Supplementary Table 1.Continued
Exclusion criteria
12. Patient who has had surgical bowel resections within the past 6 months or is planning any resection while enrolled in the study
13. Patient with an ostomy, ileoanal pouch, or symptomatic bowel stricture
14. Patient with an abdominal or perianal abscess
15. Patient who has short bowel syndrome
16. Patient who previously received stem cell transplantation in the past 3 months or patient who previously received fecal microbial
transplantation in the past 1 month
17. Patient who received NSAIDs (except topical NSAIDs and the use of low-dose aspirin for cardiovascular protection) within 14 days before
screening and during the screening visit
18. Infection(s) requiring treatment with IV anti-infectives within 30 days before the baseline visit or oral anti-infectives within 14 days before
the baseline visit
19. Patient currently receiving TPN or plans to receive TPN at any time during the course of the study
20. Patient with positive Clostridium difficile toxin stool assay result Q41during the screening period
21. Screening laboratory tests Q42and other analyses show any of the following abnormal results:
 Serum AST or ALT >2.5  the ULN
 Estimated glomerular filtration rate by simplified 4-variable MDRD formula <40 mL/min/1.73 m2
 Total WBC count <3000/mL
 ANC <1200/mL
 Platelet count <100,000/mL
 Absolute lymphocytes count <750/mL
 Hemoglobin <9 gm/dL
22. Any active or recurrent viral infection that, based on the investigator’s clinical assessment, makes the patient an unsuitable candidate for
the study, including recurrent/disseminated herpes zoster or known history of HIV
23. Hepatitis B (HBs antigen positive [þ] or detected sensitivity on the HBV DNA PCR qualitative test for HBc antibody–positive patients) or
hepatitis C virus (HCV RNA detectable in any patient with anti-HCV antibodies)
24. Patient with active or chronic recurring infections or untreated latent TB
25. History of moderate to severe congestive heart failure (NYHA class III or IV), cerebrovascular accident, and any other condition within 6
months that, in the opinion of the investigator, would put the patient at risk by participation in the study
26. Use of known strong CYP3A inhibitors (eg, clarithromycin, conivaptan, itraconazole, ketoconazole, posaconazole, telithromycin, vor-
iconazole, grapefruit juice) or strong CYP3A inducers (eg, rifampin, carbamazepine, phenytoin, St. John’s Wort) from screening through
the end of the study
27. Receipt of any live vaccine within 1 month before the screening visit or will require live vaccination during study participation, including up
to 1 month after the last dose of study drug
28. Evidence of current colonic dysplasia, history of high-grade colonic dysplasia, or history of malignancy (including of the gastrointestinal
tract) other than a successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma or localized carcinoma in situ of
the cervix
29. Has had any uncontrolled and/or clinically significant (per investigator’s judgment) illness or has had any surgical procedure within 30 days
before screening
30. Positive pregnancy test result Q43at screening (serum) or baseline (urine)
31. Female patients who are breastfeeding or considering becoming pregnant during the study
32. Patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study
33. Patient who received any investigational agent or procedure within 30 days or 5 half-lives before baseline, whichever is longer
34. History of clinically significant drug or alcohol abuse in the last 12 months
6-MP, 6-mercaptopurine; 6-TGN, 6-thioguanine nucleotide; ALT, alanine aminotransferase; ANC, absolute neutrophil count;
AST, aspartate aminotransferase; CYP3A Q44, cytochrome P45a 3A; ECG, electrocardiogram; HBV, hepatitis B virus; HCV,
hepatitis C virus; IM, intramuscular; IV, intravenous; MDRD, modification of diet in renal disease; MTX, methotrexate; NSAID,
nonsteroidal anti-inflammatory drug; NYHA, New York Heart Association; PCR, polymerase chain reaction; RBC, red blood
cell; SC, subcutaneous; TB, tuberculosis; TPN, total parenteral nutrition; UC, ulcerative colitis; ULN, upper limit of normal;
WBC, white blood cell.
Supplementary Table 2.Mandatory Corticosteroid Taper Starting on Week 2
Prednisone (or equivalent)
The taper consisted of a weekly decrease of
prednisone (or equivalent) by 5 mg/d for doses >10 mg/d until 10 mg/d was
reached, then a weekly decrease by 2.5 mg/day until discontinuation.
Budesonide Budesonide was decreased by 3 mg every week.
NOTE. If patients experienced an inadequate response during corticosteroid taper, the dose could be increased according
to the investigator’s discretion; however, if the dose was higher than the baseline dose, patients would be censored for
efficacy.
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Supplementary Table 3.Clinical and Endoscopic Endpoints at Week 52 Among Responders or Clinical Responders in Patients Randomized to Upadacitinib During the
Induction Period
Endpoints
Responders (n ¼ 54) Clinical Responders (n ¼ 94)
3 mg BID
n ¼ 20
6 mg BID
n ¼ 8
12 mg BID
n ¼ 16
24 mg QD
n ¼ 10
3 mg BID
n ¼ 32
6 mg BID
n ¼ 14
12 mg BID
n ¼ 29
24 mg QD
n ¼ 19
Endpoint at week 52
Clinical response, n (%) 11 (55) 7 (88) 11 (69) 5 (50.0) 16 (50) 10 (71) 18 (62) 8 (42)
CR-70, n (%) 11 (55) 6 (75) 12 (75) 4 (40) 15 (47) 10 (71) 18 (62) 7 (37)
Endoscopic response 25%, n (%) 12 (60) 6 (75) 12 (75) 4 (40) 13 (41) 8 (57) 16 (55) 8 (42)
Remission, n (%) 4 (20) 1 (13) 4 (25) 0 4 (13) 1 (7) 4 (14) 3 (16)
Response, n (%) 10 (50) 5 (63) 11 (69) 10 (40) 11 (34) 6 (43) 15 (52) 7 (37)
Clinical remission 1.5/1.0 in patients
with SF 2.5 and AP 2.0 at
baseline, n (%)
3 (33)
n ¼ 9
2 (33)
n ¼ 6
4 (50)
n ¼ 8
1 (20)
n ¼ 5
4 (24)
n ¼ 17
3 (30)
n ¼ 10
6 (40)
n ¼ 15
3 (33)
n ¼ 9
Clinical remission 2.8/1.0 in patients
with isolated ileal disease, n (%)
2 (67)
n ¼ 3
NA
n ¼ 0
0
n ¼ 1
NA
n ¼ 0
2 (33)
n ¼ 6
1 (50)
n ¼ 2
0
n ¼ 3
0
n ¼ 1
hs-CRP, change from baseline to
week 52, LOCF data, mean ± SD
(median)
4.3 ± 22.7
(0.4)
n ¼ 19
7.0 ± 12.7
(1.1)
20.4 ± 18.8
(17.2)
6.2 ± 35.8
(3.1)
n ¼ 9
2.8 ± 18.9
(0.2)
n ¼ 30
2.1 ± 18.4
(1.1)
13.9 ± 37.1
(8.0)
n ¼ 28
10.2 ± 55.7
(0.0)
n ¼ 17
Fecal calprotectin, change from
baseline to week 52, LOCF data,
mean ± SD (median)
51.9 ±
2651.0
(422.0)
n ¼ 16
524.1 ± 521.3
(235.0)
n ¼ 7
3047.5 ±
2509.3
(2305.5)
n ¼ 10
2371.8 ±
3787.0
(748.0)
n ¼ 4
1.0 ± 2457.2
(100.5)
n ¼ 26
239.3 ± 1443.1
(188.5)
n ¼ 12
2617.4 ±
3232.0
(1879.0)
n ¼ 18
1510.3 ±
2773.9
(120.5)
n ¼ 10
IBDQ, change from baseline to week
52, observed data, mean ± SD
(median)
43.9 ± 38.1
(40.0)
n ¼ 14
56.4 ± 14.5
(51.5)
82.3 ± 35.6
(83.5)
n ¼ 14
45.3 ± 49.9
(37.0)
n ¼ 7
42.8 ± 44.1
(33.0)
n ¼ 22
46.6 ± 27.8
(48.0)
n ¼ 13
70.7 ± 47.0
(80.0)
n ¼ 23
26.6 ± 53.1
(9.5)
n ¼ 14
Endpoints in patients with corticosteroid
use at baseline
3 mg BID
n ¼ 8
6 mg BID
n ¼ 2
12 mg BID
n ¼ 8
24 mg QD
n ¼ 5
3 mg BID
n ¼ 15
6 mg BID
n ¼ 6
12 mg BID
n ¼ 14
24 mg
QD
n ¼ 8
Corticosteroid-free clinical remission
1.5/1.0, n (%)
2 (25) 2 (100) 5 (63) 0 4 (27) 3 (50) 6 (43) 1 (13)
Corticosteroid-free endoscopic
remission
2 (25) 0 4 (50) 0 2 (13) 1 (17) 5 (36) 1 (13)
Corticosteroid-free remission at week Q45,
n (%)
2 (25) 0 3 (38) 0 2 (13) 0 3 (21) 1 (13)
NOTE. Data are n (%) using nonresponder imputation unless indicated otherwise. Clinical responders were defined as patients who achieved clinical response at week 16,
and responders were defined as patients who achieved both clinical response and endoscopic response 25% at week 16. Clinical remission 1.5/1.0 was defined as
average daily very soft/liquid SF 1.5 and average daily AP score 1, without worsening from baseline. Clinical remission 2.8/1.0 was defined as average daily very soft/
liquid SF 2.8 and average daily SP score 1, neither worse than baseline, among patients with baseline average daily very soft/liquid SF 4.0 or average daily AP score
2.0. Clinical response was defined as 30% reduction from baseline in average daily very soft/liquid SF and/or average daily AP score, neither worse than baseline.
Remission was defined as combined clinical remission 1.5/1.0 and endoscopic remission, and response was defined as combined clinical response and endoscopic
response 25%.
BID, twice daily; LOCF, last observation carried forward; NA, not applicable; QD, once daily; SD, standard deviation.
aRisk Q46difference: upadacitinib higher dose vs upadacitinib 3 mg BID.
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Supplementary Table 4.Changes From Baseline in Laboratory Values at Week 16
Laboratory parameter
Placebo
n ¼ 37
Upadacitinib
3 mg BID
n ¼ 39
6 mg BID
n ¼ 37
12 mg BID
n ¼ 36
24 mg BID
n ¼ 36
24 mg QD
n ¼ 35
Hemoglobin, g/L
Mean ± SD 2.3 ± 9.6 0.9 ± 10.5 1.3 ± 10.6 1.0 ± 14.5 1.4 ± 9.9 1.4 ± 11.4
Median 0.5 1.0 2.0 1.0 2.0 2.0
Lymphocytes, cells 109/L
Mean ± SD 0.03 ± 0.72 0.08 ± 0.66 0.03 ± 0.99 0.40 ± 1.04 0.24 ± 1.01 0.27 ± 0.84
Median 0.00 0.01 0.18 0.07 0.12 0.19
Neutrophils, cells 109/L
Mean ± SD 0.61 ± 3.15 0.61 ± 2.91 1.22 ± 2.99 1.16 ± 3.95 1.26 ± 2.81 1.05 ± 2.81
Median 0.35 0.16 0.74 1.51 1.38 0.62
Platelets count, 109/L
Mean ± SD 25.9 ± 71.2 2.4 ± 65.3 3.9 ± 97.1 11.6 ± 116.9 24.4 ± 52.5 12.4 ± 85.5a
Median 13.0 13.0 1.0 26.0 17.0 6.0
ALT, U/L
Mean ± SD 2.1 ± 31.1 3.3 ± 20.5 1.3 ± 22.5 7.4 ± 13.9 4.1 ± 12.1 5.4 ± 17.5
Median 0.0 2.0 2.0 2.0 4.0 3.0
AST, U/L
Mean ± SD 4.5 ± 20.6 6.4 ± 23.9 4.9 ± 14.2 6.0 ± 9.4 9.0 ± 9.0 5.6 ± 11.0
Median 1.0 1.5 6.0 6.0 8.0 1.1
Creatinine, mmol/L
Mean ± SD 3.7 ± 7.7 0.3 ± 9.6 4.6 ± 14.3 7.5 ± 25.6 1.7 ± 6.8 3.8 ± 9.8
Median 5.2 0.1 1.0 1.2 2.4 3.1
CPK, U/L
Mean ± SD 9.1 ± 49.7a 164.1 ± 822.8 82.1 ± 84.5 106.0 ± 115.4 228.0 ± 434.5b 78.8 ± 229.7
Median 1.0 17.0 54.0 82.0 113.0 31.0
Total cholesterol, mmol/L
Mean ± SD 0.10 ± 0.68 0.19 ± 0.81 0.17 ± 0.77 0.44 ± 0.94b 0.70 ± 0.68c 0.29 ± 0.78
Median 0.08 0.15 0.25 0.54 0.75 0.21
HDL cholesterol, mmol/L
Mean ± SD 0.02 ± 0.34 0.13 ± 0.48 0.05 ± 0.35 0.15 ± 0.28a 0.48 ± 0.47c 0.01 ± 0.26
Median 0.06 0.04 0.07 0.18 0.49 0.03
LDL cholesterol, mmol/L
Mean ± SD 0.01 ± 0.47 0.05 ± 0.51 0.15 ± 0.57 0.43 ± 0.69d 0.42 ± 0.48d 0.20 ± 0.62
Median 0.00 0.08 0.21 0.37 0.44 0.27
Triglyceride, mmol/L
Mean ± SD 0.09 ± 0.68 0.09 ± 0.61 0.08 ± 0.63 0.28 ± 0.86a 0.43 ± 0.67b 0.40 ± 1.18
Median 0.17 0.03 0.13 0.30 0.26 0.25
ALT, alanine aminotransferase; AST, aspartate aminotransferase. BID, twice daily; HDL, high-density lipoprotein; LDL,
low-density lipoprotein; QD, once daily; SD, standard deviation.
aSignificant Q47differences with placebo at P < .1.
bSignificant differences with placebo at P < .05.
cSignificant differences with placebo at P < .001.
dSignificant differences with placebo at P < .01.
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Supplementary Table 5.Changes From Baseline in Laboratory Values at Week 52
Laboratory parameter 3 mg BID n ¼ 42 6 mg BID n ¼ 21 12 mg BID n ¼ 43 24 mg QD n ¼ 24
Hemoglobin, g/L
Mean ± SD 0.7 ± 11.7 2.5 ± 12.5 1.9 ± 13.8 1.8 ± 14.6
Median 0.0 5.0 n ¼ 17 4.0 5.0
Lymphocytes, cells 109/L
Mean ± SD 0.4 ± 0.7 0.4 ± 0.7 0.5 ± 0.9 0.1 ± 0.9
Median 0.3 0.2 n ¼ 17 0.4 0.0
Neutrophils, cells 109/L
Mean ± SD 1.6 ± 3.2 0.2 ± 2.7 1.2 ± 3.4 1.6 ± 3.8
Median 1.6 0.0 n ¼ 17 1.1 1.6
Platelets count, 109/L
Mean ± SD 15.0 ± 112.3 0.3 ± 73.9 14.9 ± 115.7 11.3 ± 136.0
Median 8.0 12.0 n ¼ 17 7.0 24.0
ALT, U/L
Mean ± SD 4.9 ± 33.8 3.8 ± 18.6 9.8 ± 23.8 5.5 ± 17.5
Median 3.0 0.0 n¼19 5.0 7.0
AST, U/L
Mean ± SD 5.7 ± 18.7 4.3 ± 9.5 11.8 ± 14.6 9.8 ± 18.6
Median 4.0 3.0 n ¼ 20 10.0 11.0 n ¼ 23
Creatinine, mmol/L
Mean ± SD 4.6 ± 9.5 4.2 ± 10.2 3.9 ± 11.2 1.7 ± 8.9
Median 3.2 5.1 3.5 3.8
CPK, U/L
Mean ± SD 122.9 ± 205.6 165.0 ± 543.6 99.8 ± 118.1 171.9 ± 333.6
Median 72.0 36.0 90.0 85.5
Total cholesterol, mmol/L
Mean ± SD 0.22 ± 1.05 0.38 ± 1.08 0.67 ± 0.85 0.42 ± 0.83
Median 0.23 0.28 0.75 0.48
HDL cholesterol, mmol/L
Mean ± SD 0.08 ± 0.31 0.13 ± 0.42 0.21 ± 0.31 0.10 ± 0.32
Median 0.10 0.19 0.18 0.10
LDL cholesterol, mmol/L
Mean ± SD 0.15 ± 0.89 0.33 ± 0.90 0.49 ± 0.64 0.29 ± 0.60
Median 0.12 n ¼ 40 0.24 0.57 0.27
Triglyceride, mmol/L
Mean ± SD 0.21 ± 1.75 0.31 ± 0.97 0.08 ± 0.66 0.09 ± 0.64
Median 0.04 0.09 0.03 0.12
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BID, twice daily; HDL, high-density lipoprotein; LDL,
low-density lipoprotein; QD, once daily; SD, standard deviation.
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